(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of -4.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.63%.
Moderna's revenue in 2024 is $5,050,000,000.On average, 10 Wall Street analysts forecast MRNA's revenue for 2024 to be $1,231,263,536,445, with the lowest MRNA revenue forecast at $1,087,533,248,076, and the highest MRNA revenue forecast at $1,305,293,599,071. On average, 8 Wall Street analysts forecast MRNA's revenue for 2025 to be $1,245,891,727,367, with the lowest MRNA revenue forecast at $1,070,312,305,932, and the highest MRNA revenue forecast at $1,637,142,691,770.
In 2026, MRNA is forecast to generate $1,797,932,475,951 in revenue, with the lowest revenue forecast at $1,215,118,134,393 and the highest revenue forecast at $2,445,911,938,890.